Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled date : 2021 - 10 - 28 save search
Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.1%
H: 1.44%
C: 0.96%
collaboration cancer breast cancer trial keytruda
STAG Industrial Closes Sale of 350,000 Square Foot Facility Located in Taunton, Massachusetts
Published: 2021-10-28 (Crawled : 21:00) - stagindustrial.com
STAG | $34.93 1.6% 0.0% 1.5M
|
Finance
|
| O: -1.81%
H: 1.18%
C: -0.87%
trial
STAG Industrial Announces Third Quarter 2021 Results
Published: 2021-10-28 (Crawled : 21:00) - stagindustrial.com
STAG | $34.93 1.6% 0.0% 1.5M
|
Finance
|
| O: -1.81%
H: 1.18%
C: -0.87%
results trial
Johnson Controls to present at the Baird 2021 Global Industrial Conference
Published: 2021-10-28 (Crawled : 21:00) - prnewswire.com
GIC | $40.52 0.87% 0.0% 56K
|
Retail Trade
|
| O: 0.18%
H: 4.15%
C: 2.71%
JCI | News | $63.66 -0.17% 0.0% 5.2M
|
Producer Manufacturing
|
| O: -0.63%
H: 1.16%
C: 0.55%
trial conference
Ecolab to Acquire Purolite, a Leading Global Provider of Fast-Growing, High Value Separation and Purification Solutions to Life Sciences and Critical Industrial Markets
Published: 2021-10-28 (Crawled : 21:00) - globenewswire.com
ECL | News | $218.16 -0.48% 0.69% 2.6M
|
Process Industries
|
| O: -0.53%
H: 1.54%
C: 1.09%
growing life science trial
Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology
Published: 2021-10-28 (Crawled : 20:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.17%
H: 1.06%
C: 0.39%
ema phase 3 trial
Clinical Trial Manager, JD
Published: 2021-10-28 (Crawled : 18:00) - atyrpharma.com
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: 0.12%
H: 2.89%
C: 2.31%
trial
XBiotech to Launch Novel Candidate Therapy for StrokeCompany Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke
Published: 2021-10-28 (Crawled : 18:00) - biospace.com/
XBIT | $7.98 0.89% 0.88% 76K
|
Health Technology
|
| O: 0.56%
H: 4.35%
C: 0.7%
new drug stroke test therapy biotech drug iot train
Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Published: 2021-10-28 (Crawled : 14:00) - biospace.com/
RFL 4 | $1.76 2.92% 0.0% 26K
|
Finance
|
| O: -78.09%
H: 36.16%
C: 22.39%
myeloid leukemia cancer leukemia phase 3 trial pancreatic cpi-613 pancreas acute myeloid leukemia
Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate Cancer
Published: 2021-10-28 (Crawled : 14:00) - biospace.com/
CADL | $5.17 -5.31% -5.61% 520K
|
|
| O: -1.22%
H: 1.23%
C: -0.97%
ongoing prostate cancer injection cancer phase 3 trial
Cardinal Health Awarded FDA Funding to Assess Real World Evidence Results Against Clinical Trials
Published: 2021-10-28 (Crawled : 14:00) - biospace.com/
CAH | $108.19 2.07% 0.0% 1.5M
|
Distribution Services
|
| O: 0.28%
H: 0.96%
C: 0.3%
funding fda clinical trials results trials trial
TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled Formulation of Niclosamide to Treat COVID-19
Published: 2021-10-28 (Crawled : 14:00) - globenewswire.com
TFFP | $3.35 6.86% 6.42% 3.7K
|
Health Technology
|
| O: 0.0%
H: 3.71%
C: -1.28%
covid clinical trials trials trial approval
AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease
Published: 2021-10-28 (Crawled : 13:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.01%
H: 1.39%
C: 1.18%
disease parkinson phase 3 trial levodopa
HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer
Published: 2021-10-28 (Crawled : 12:15) - biospace.com/
HCWB | $1.66 0.0% 1.4K
|
|
| O: 60.62%
H: 50.32%
C: 0.85%
fda clearance fda phase 1 cancer phase 1b trial pancreatic hcw9218 pancreas phase 2b clearance
Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
OPTN | $0.8951 -3.51% -3.64% 650K
|
Health Services
|
| O: 1.54%
H: 2.03%
C: 0.0%
trial
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: -4.1%
H: 0.0%
C: -4.24%
cancer phase 3 ovarian cancer trial enroll
Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
IMUX | $1.2 -5.51% -5.83% 360K
|
Health Technology
|
| O: -0.23%
H: 6.12%
C: 6.12%
phase 2 trial enroll ulcerative colitis imu-838
PaxMedica Presents Clinical Data and New Analyses at the 2021 American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
PXMD | $0.7665 0.45% 0.44% 520K
|
Health Technology
| Email alert
Add to watchlist
Landos Biopharma Announces First Subject Dosed in a Phase 1 Study of LABP-104 for Systemic Lupus Erythematosus
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
LABP | $21.74 -0.05% -0.05% 15K
|
|
| O: -1.23%
H: 2.63%
C: -2.12%
ema biopharma phase 1 lupus phase 2
Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patients
Published: 2021-10-28 (Crawled : 11:00) - biospace.com/
EWTX | $15.23 -1.42% -1.44% 540K
|
Manufacturing
|
| O: 2.35%
H: 3.77%
C: -3.38%
muscular dystrophy phase 1 positive results topline
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.